Chiara Ambrogio

27PUBLICATIONS
170CO-AUTHORS
Molecular targetsHaematological tumoursApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Predictive and prognostic markersTumour immunology
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (27)

|Sep 30, 2026
FAK inhibitor and RAF/MEK clamp avutometinib enhance KRAS G12C inhibitor efficacy in preclinical models of non-small cell lung cancer.

|Jun 22, 2026
EML4-ALK mediates resistance to KRAS G12C inhibition and induces an oncogenic dependency by rewiring signaling through the wild-type RAS pathway.

|May 27, 2026
Targeted KRASG12V Degradation In Vivo Elicits Lung Adenocarcinoma Regression with Subsequent Relapse from Dysregulated Proteolysis.

|Mar 12, 2025
SOS1 inhibitor BI-3406 shows in vivo antitumor activity akin to genetic ablation and synergizes with a KRASG12D inhibitor in KRAS LUAD.

Fernando C Baltanás, Maximilian Kramer-Drauberg, Rósula García-Navas

|Mar 07, 2025
ALK in cancer: from function to therapeutic targeting.

Claudia Voena, Chiara Ambrogio, Fabio Iannelli

|Jan 22, 2025
Oncogenic mutant KRAS inhibition through oxidation at cysteine 118.

Maximilian Kramer-Drauberg, Ettore Petrini, Alessia Mira

Pageof 5

Frequent Collaborators

9 joint publications

Roberto Chiarle

7 joint publications

Claudia Voena

7 joint publications

Enrico Patrucco

5 joint publications

Xing-Xiao Li